This review discusses the current state of multicancer early detection tests, the role of machine learning in their ...

Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk myelodysplastic syndrome.

Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

Scott Eggener, MD, gave a talk at the LUGPA annual meeting titled “Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments.” ...

An expert discusses emerging developments in the use of systemic immunotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC) from the perspective of a radiation oncologist, highlighting how ...

An expert discusses strategies for monitoring response to treatment, including observation, Epstein-Barr virus (EBV) titers, ...

An expert discusses the treatment approach for recurrence in Case 1, evaluating the combination of toripalimab + gemcitabine/cisplatin for recurrent disease and considering the potential for ...

An expert discusses the use of toripalimab in the treatment of recurrent and metastatic nasopharyngeal carcinoma (NPC) through clinical case introductions.

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea ...